COVID-19/ Sore throat; This spontaneous case was reported by a pharmacist and describes the occurrence of COVID-19 (COVID-19/ Sore throat) in a 35-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011F21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 and Exercise induced asthma. Concurrent medical conditions included Peanut allergy.    On 05-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (COVID-19/ Sore throat). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 11-May-2022 to 16-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19/ Sore throat) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: negative (Negative) negative and positive (Positive) positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication has been provided.  The patient previously received COVID-19 vaccine of unknown company. Patient started paxlovid on day 2 of covid Dx, and finished on day 7, when the symptom  disappear and antigen negative on day 10 but it relapsed with minor sore throat and antigen positive on day 12 . Device Date : 21May2022  Company comment:  This spontaneous case concerns a 35-year-old, male patient with underlying medical history of exercise induced asthma, who experienced the unexpected, non-serious adverse event of special interest of COVID-19, which occurred approximately 6 months 4 days after receiving the third dose of mRNA-1273 vaccine. Patient contracted  COVID-19 and was prescribed with Nirmatrelvir, Ritonavir (Paxlovid) on day 2 of the diagnosis. He completed treatment in 5 days (day 7 of diagnosis), was symptom free and tested negative on antigen test on the day 10 of diagnosis. After two days the patient felt minor sore throat and tested positive on repeat antigen test(day 12 of diagnosis). Further details on other diagnostic or laboratory test done were not provided in the case. The patient's underlying medical history of exercise induced asthma may be considered as a risk factor for COVID-19 in this case. The benefit-risk relationship of mRNA-1273 is not affected by this report. Sender's Comments: This spontaneous case concerns a 35-year-old, male patient with underlying medical history of exercise induced asthma, who experienced the unexpected, non-serious adverse event of special interest of COVID-19, which occurred approximately 6 months 4 days after receiving the third dose of mRNA-1273 vaccine. Patient contracted  COVID-19 and was prescribed with Nirmatrelvir, Ritonavir (Paxlovid) on day 2 of the diagnosis. He completed treatment in 5 days (day 7 of diagnosis), was symptom free and tested negative on antigen test on the day 10 of diagnosis. After two days the patient felt minor sore throat and tested positive on repeat antigen test(day 12 of diagnosis). Further details on other diagnostic or laboratory test done were not provided in the case. The patient's underlying medical history of exercise induced asthma may be considered as a risk factor for COVID-19 in this case. The benefit-risk relationship of mRNA-1273 is not affected by this report.